Get Our FREE Newsletter

Sign Up

GenSight Gets Fast Track Designation For Optogenetic Therapy GS030 To Treat Retinitis Pigmentosa

Spread the love

(RTTNews) – GenSight Biologics (SIGHT), a company focused on developing and commercializing gene therapies, on Tuesday said the U.S. Food and Drug Administration or FDA has granted Fast Track Designation to GS030, which combines AAV2-based gene therapy with optogenetics to treat

This post was originally published on this site